Olverembatinib Combined With Reduced-Intensity Chemotherapy and Venetoclax for de Novo Ph+ ALL
Status:
Recruiting
Trial end date:
2025-03-01
Target enrollment:
Participant gender:
Summary
The introduction of TKIs has greatly improved the prognosis of Ph+ ALL patients. The
third-generation TKI ponatinib in combination with chemotherapy has demonstrated superior
efficacy to first- and second-generation TKIs. However, unfortunately, ponatinib is not
available in mainland China. Olverembatinib is the only third-generation TKI drug currently
approved in mainland China. Venetoclax is an oral selective inhibitor of Bcl-2, and small
exploratory clinical studies have demonstrated that venetoclax in combination with ponatinib
showed high rates of CR as well as molecular response in relapsed/refractory Ph+ ALL. This
study will explore the safety and efficacy of olverembatinib in combination with
reduced-intensity chemotherapy and venetoclax in patients with newly diagnosed Ph+ ALL.